Toscafund Asset Management LLP acquires Spire Healthcare Group plc (2026)

Deal facts

Buyer: Toscafund Asset Management LLP
Target: Spire Healthcare Group plc
Deal value: Not disclosed
Announced: 14 May 2026
Status: Possible offer
Sector: Healthcare
Country: United Kingdom
Consideration: cash, shares

Sources

What we know

Toscafund Asset Management LLP has agreed to acquire Spire Healthcare Group plc in a proposed transaction within the UK healthcare sector. The deal, announced on 14 May 2026, involves a mixed consideration structure comprising both cash and shares. Both the acquiring entity and the target company are based in the United Kingdom. The transaction is currently classified as a possible offer, with the final deal type yet to be confirmed by the parties involved.

No specific financial value for the acquisition has been reported at this stage. The completion date remains unconfirmed as the process is still in its early phases. Regulatory approvals and other standard conditions will likely need to be satisfied before the transaction can proceed to a final conclusion. The parties are expected to provide further updates regarding the progress of the negotiations and the definitive terms of the agreement.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

14 May 2026Possible offer
Statement regarding possible offer
FOR IMMEDIATE RELEASE Spire Healthcare Group plc ("Spire Healthcare", the "Company") Statement regarding possible offer As part of the ongoing strategic review and following the announcement on 20 March 2026 that the Board of Spire Healthcare (the "Board") remained in discussions in relation to a potential sale of the Company, the Board confirms that it has received a non-binding
LSE RNS

OpinionExit Mode editorial

We see a potential shift in the UK healthcare landscape with the announced possible offer by Toscafund Asset Management LLP to acquire Spire Healthcare Group plc. This is a domestic deal between two UK entities, announced on 14 May 2026, involving a mix of cash and shares as consideration. The status remains a possible offer, which signals that terms are not yet finalised and the path to completion is not guaranteed. For the SME founder watching from the sidelines, this highlights how even established public companies in essential sectors can become targets for asset managers looking to restructure or consolidate operations.

The use of a mixed consideration package of cash and shares introduces specific mechanics that require careful navigation. A cash element provides immediate liquidity, while the share component ties the seller to the future performance of the combined entity. In a healthcare context, this structure often invites scrutiny regarding long-term service commitments and capital allocation. Furthermore, any change of control in a major private hospital group triggers regulatory checkpoints. The Competition and Markets Authority will likely assess whether this combination reduces competition in local markets or creates anti-trust issues. You must also consider change-of-control covenants in existing lender agreements, as these could accelerate debt repayments or require immediate renegotiation if the deal proceeds.

Our view is that the ambiguity of a possible offer creates a unique window for due diligence. The lack of a stated value means the market is currently pricing in uncertainty rather than a definitive premium. This situation demands that you understand the buyer's intent beyond the headline. Are they seeking a quick flip or a long-term hold? The answer dictates how you should approach your own exit planning. Do not assume the deal will close simply because it has been announced. The regulatory clearance process in the UK can be lengthy, and the mixed consideration structure adds layers of complexity to the final agreement.

For the founder reading this, your immediate action should be to review your own shareholder agreements and debt covenants for change-of-control triggers. Identify exactly what rights you hold if a third party makes a formal offer for your business, and determine if you need to secure independent valuation advice before any formal negotiations begin.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More unknown deals More from Toscafund Asset Management LLP All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

26 June 2026Firm intentionHealthcare

Defender Opportunity LLC to acquire Non-Invasive Monitoring Systems, Inc.

Defender Opportunity LLC has agreed to acquire Non-Invasive Monitoring Systems, Inc. in a transaction structured as a loan note consideration. The deal was announced on…

Buyer: Defender Opportunity LLC
Target: Non-Invasive Monitoring Systems, Inc.
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals United States deals

29 May 2026AbandonedHealthcare

Tooru PLC to acquire Mylky B.V

Tooru PLC has agreed to acquire Mylky B.V in a transaction within the Healthcare sector. The deal was announced on 29 May 2026, involving a buyer based in Great Britain…

Buyer: Tooru PLC
Target: Mylky B.V
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals Netherlands deals

15 May 2026Firm intentionHealthcare

TA Associates (UK), LLP to acquire Advanced Medical Solutions Group plc

TA Associates (UK), LLP has agreed to acquire Advanced Medical Solutions Group plc in a transaction within the Healthcare sector. The deal was announced on 15 May 2026,…

Buyer: TA Associates (UK), LLP
Target: Advanced Medical Solutions Group plc
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals United Kingdom deals

22 March 2026In reviewHealthcare

KOHLBERG / MONTAGU to acquire TELEFLEX OEM BUSINESS

KOHLBERG / MONTAGU has agreed to acquire the TELEFLEX OEM Business in a transaction announced on 22 March 2026. The deal involves a company operating within the NaceV2Se…

Buyer: KOHLBERG / MONTAGU
Target: TELEFLEX OEM BUSINESS
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals In review deals

8 March 2026In reviewHealthcare

SK CAPITAL to acquire SWIXX BIOPHARMA

SK CAPITAL has agreed to acquire SWIXX BIOPHARMA in a transaction announced on 8 March 2026. The deal involves the biopharmaceutical sector, specifically within the whol…

Buyer: SK CAPITAL
Target: SWIXX BIOPHARMA
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals In review deals

Buyer history

Toscafund Asset Management LLP

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive